keyword
Keywords estradiol levels and aromatase...

estradiol levels and aromatase inhibitors in breast cancer

https://read.qxmd.com/read/35343852/safety-of-prasterone-in-breast-cancer-survivors-treated-with-aromatase-inhibitors-the-vibra-pilot-study
#21
JOURNAL ARTICLE
E Mension, I Alonso, I Cebrecos, N Castrejon, M Tortajada, I Matas, S Gómez, L Ribera, S Anglès-Acedo, C Castelo-Branco
BACKGROUND: Due to safety concerns on estrogen-based treatments for genitourinary syndrome of menopause (GSM) in breast cancer survivors (BCS), new options are appearing, such as androgen-based treatments, which according to proprieties would not be transformed systemically to estrogens in patients receiving aromatase inhibitors (AIs). OBJECTIVE: The aim of this pilot study is to assess the security and efficacy of vaginal prasterone (dehydroepiandrostenedione [DHEA]) in BCS treated with AIs...
October 2022: Climacteric: the Journal of the International Menopause Society
https://read.qxmd.com/read/35316932/management-of-genitourinary-syndrome-of-menopause-in-breast-cancer-survivors-an-update
#22
REVIEW
Daniel María Lubián López
There is increasing attention about managing the adverse effects of adjuvant therapy (Chemotherapy and anti-estrogen treatment) for breast cancer survivors (BCSs). Vulvovaginal atrophy (VVA), caused by decreased levels of circulating estrogen to urogenital receptors, is commonly experienced by this patients. Women receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM), that it can in turn lead to pain, discomfort, impairment of sexual function and negatively impact on multiple domains of quality of life (QoL)...
February 24, 2022: World Journal of Clinical Oncology
https://read.qxmd.com/read/34958096/simultaneous-quantification-of-aromatase-inhibitors-and-estrogens-in-postmenopausal-breast-cancer-patients
#23
JOURNAL ARTICLE
Bjørn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Håvard Søiland, Jürgen Geisler, Tone Hoel Lende, Per Eystein Lønning, Jørn V Sagen, Gunnar Mellgren, Bjørg Almås
CONTEXT: Currently there are no assays that can simultaneously quantify serum levels of the third generation aromatase inhibitors (AI); letrozole, anastrozole, and exemestane, and the ultralow levels of estrogens in postmenopausal breast cancer patients on AI treatment. Such measurements may be pivotal for the determination of optimal and individualized treatment regimens. We aimed at developing an LC-MS/MS method for simultaneous assessment of letrozole, anastrozole, exemestane and 17-hydroxy-exemestane as well as subpicomolar levels of estradiol and estrone...
December 27, 2021: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/34656436/fertility-preservation-for-women-with-breast-cancer-before-chemotherapy-a-systematic-review-and-meta-analysis
#24
REVIEW
Chih-Ning Chen, Lu-Te Chang, Chi-Huang Chen, Ka-Wai Tam
The preservation of fertility in women of childbearing age with breast cancer is challenging because the time for ovarian stimulation is restricted and only a limited number of oocytes can be retrieved before gonadotoxic therapies. The aim of this meta-analysis was to evaluate the fertility preservation outcomes after ovarian stimulation with various protocols in women with breast cancer. PubMed, Embase and the Cochrane Library were searched. Twenty-two studies comparing the outcomes of women with breast cancer receiving random-start ovarian stimulation or conventional protocol; single or double ovarian stimulation cycles; and coadministration of aromatase inhibitors or tamoxifen were included...
February 2022: Reproductive Biomedicine Online
https://read.qxmd.com/read/34638451/blocking-estrogen-synthesis-leads-to-different-hormonal-responses-in-canine-and-human-triple-negative-inflammatory-breast-cancer
#25
JOURNAL ARTICLE
Sara Caceres, Beatriz Monsalve, Angela Alonso-Diez, Belén Crespo, Maria Jose Illera, Paloma Jimena de Andres, Gema Silvan, Juan Carlos Illera
Blocking estrogen synthesis by inhibitors of estrogen synthesis is a widely used therapy against estrogen receptor-positive tumors. However, these therapies are less effective in negative expression tumors. Therefore, this study determined the effectiveness of anti-aromatase and anti-sulfatase therapies in canine and human inflammatory breast cancer. Cell cultures and xenografts from IPC-366 and SUM149 were treated with different doses of letrozole (anti-aromatase) and STX-64 (anti-sulfatase), in order to observe their effectiveness in terms of cell proliferation, tumor progression, and the appearance of metastases and hormonal profiles...
October 2, 2021: Cancers
https://read.qxmd.com/read/34414109/circulating-tumor-dna-to-interrogate-the-safety-of-letrozole-associated-controlled-ovarian-stimulation-for-fertility-preservation-in-breast-cancer-patients
#26
JOURNAL ARTICLE
Françoise Rothé, Matteo Lambertini, Oranite Goldrat, Marion Maetens, Yacine Bareche, Jeremy Blanc, Ghizlane Rouas, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Isabelle Demeestere
BACKGROUND: Current fertility preservation strategies for young breast cancer patients planning a future motherhood include the association of controlled ovarian stimulation with the aromatase inhibitor letrozole (let-COS) to harvest mature oocytes while maintaining low estradiol levels. Despite this is a widely adopted protocol, the safety of let-COS on breast cancer outcomes has been poorly investigated and its use remains off-label. We assessed the safety of let-COS in breast cancer patients using circulating tumor DNA (ctDNA) as a surrogate biomarker of disease recurrence...
2021: Frontiers in Oncology
https://read.qxmd.com/read/34370654/therapeutic-options-for-the-management-of-aromatase-inhibitor-associated-bone-loss
#27
REVIEW
Agostino Gaudio, Anastasia Xourafa, Rosario Rapisarda, Pietro Castellino
BACKGROUND: Breast cancer is the most commonly occurring cancer in women worldwide. Early breast cancer is a kind of invasive neoplasm that has not proliferated beyond the breast or the axillary lymph nodes. Current therapeutic strategies for breast cancer mainly include local therapies such as surgery or radiotherapy and systemic therapies like chemotherapy, endocrine, and targeted therapy. Nowadays, the adjuvant treatment for hormone receptor-positive early breast cancer in postmenopausal women remains the main effective systemic therapy which can improve disease- free survival and overall survival; it involves several endocrine treatment regimens, including Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors (AIs), or a combination of them...
2022: Endocrine, Metabolic & Immune Disorders Drug Targets
https://read.qxmd.com/read/34216815/alternative-dosing-of-exemestane-in-postmenopausal-women-with-er-positive-breast-cancer-design-and-methods-of-a-randomized-presurgical-trial
#28
RANDOMIZED CONTROLLED TRIAL
Aliana Guerrieri-Gonzaga, Davide Serrano, Parjhitham Thomas, Katherine D Crew, Nagi B Kumar, Sara Gandini, Lana A Vornik, Jack Lee, Sara Cagnacci, Elisa Vicini, Chiara A Accornero, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Tania B Webber, Powel H Brown, Eva Szabo, Brandy Heckman-Stoddard, Bernardo Bonanni
INTRODUCTION: Aromatase inhibitors are effective in lowering breast cancer incidence among postmenopausal women, but adverse events represent a barrier to their acceptability and adherence as a preventive treatment. This study aims to assess whether lowering exemestane schedule may retain biological activity while improving tolerability in breast cancer patients. METHODS/DESIGN: We are conducting a, pre-surgical, non-inferiority phase IIb study in postmenopausal women with newly diagnosed estrogen receptor-positive breast cancer...
August 2021: Contemporary Clinical Trials
https://read.qxmd.com/read/34016642/steroid-ligands-the-forgotten-triggers-of-nuclear-receptor-action-implications-for-acquired-resistance-to-endocrine-therapy
#29
JOURNAL ARTICLE
Rachel Bleach, Stephen F Madden, James Hawley, Sara Charmsaz, Cigdem Selli, Katherine M Sheehan, Leonie S Young, Andrew H Sims, Pavel Souček, Arnold D Hill, Marie McIlroy
PURPOSE: There is strong epidemiologic evidence indicating that estrogens may not be the sole steroid drivers of breast cancer. We hypothesize that abundant adrenal androgenic steroid precursors, acting via the androgen receptor (AR), promote an endocrine-resistant breast cancer phenotype. EXPERIMENTAL DESIGN: AR was evaluated in a primary breast cancer tissue microarray ( n = 844). Androstenedione (4AD) levels were evaluated in serum samples ( n = 42) from hormone receptor-positive, postmenopausal breast cancer...
July 15, 2021: Clinical Cancer Research
https://read.qxmd.com/read/33911053/suppressed-estrogen-supply-via-extra-ovarian-progesterone-receptor-membrane-component-1-in-menopause
#30
JOURNAL ARTICLE
Sang R Lee, Hyun Yang, Seong Lae Jo, Young Ho Lee, Hye Won Lee, Bae-Keun Park, Eui-Ju Hong
In post-menopausal women, intra-mammary estrogen, which is converted from extra-ovarian estrone (E1), promotes the growth of breast cancer. Since the aromatase inhibitor letrozole does not suppress 17β-estradiol (E2) production from E1, high intra-mammary E1 concentrations impair letrozole's therapeutic efficacy. Progesterone receptor membrane component 1 (Pgrmc1) is a non-classical progesterone receptor associated with breast cancer progression. In the present study, we introduced a Pgrmc1 heterozygous knockout (hetero KO) murine model exhibiting low Pgrmc1 expression, and observed estrogen levels and steroidogenic gene expression...
January 29, 2021: Journal of Biomedical Research
https://read.qxmd.com/read/33875787/high-estrogen-receptor-alpha-activation-confers-resistance-to-estrogen-deprivation-and-is-required-for-therapeutic-response-to-estrogen-in-breast-cancer
#31
JOURNAL ARTICLE
Nicole A Traphagen, Sarah R Hosford, Amanda Jiang, Jonathan D Marotti, Brooke L Brauer, Eugene Demidenko, Todd W Miller
Estrogen receptor alpha (ER)-positive breast cancer is commonly treated with endocrine therapies, including antiestrogens that bind and inhibit ER activity, and aromatase inhibitors that suppress estrogen biosynthesis to inhibit estrogen-dependent ER activity. Paradoxically, treatment with estrogens such as 17b-estradiol can also be effective against ER+ breast cancer. Despite the known efficacy of estrogen therapy, the lack of a predictive biomarker of response and understanding of the mechanism of action have contributed to its limited clinical use...
May 2021: Oncogene
https://read.qxmd.com/read/33721121/an-updated-review-of-epidemiology-risk-factors-and-management-of-male-breast-cancer
#32
REVIEW
Noman Ahmed Jang Khan, Maria Tirona
Unlike female breast cancer, male breast cancer (MBC) is rare and not very well understood. Prospective data in the management of MBC are lacking and majority of treatment strategies are adopted from the established guidelines for breast cancer in women. The understanding of biology, clinical presentation, genetics, and management of MBC is evolving but there still remains a large knowledge gap due to the rarity of this disease. Older age, high estradiol levels, klinefelter syndrome, radiation exposure, gynecomastia, family history of breast cancer, BRCA2 and BRCA1 mutation are some of the known risk factors for MBC...
March 15, 2021: Medical Oncology
https://read.qxmd.com/read/33710439/monitoring-serum-estradiol-levels-in-breast-cancer-patients-during-extended-adjuvant-letrozole-treatment-after-five-years-of-tamoxifen-a-prospective-trial
#33
JOURNAL ARTICLE
Mária Faltinová, Leena Vehmanen, Heli Lyytinen, Mikko Haanpää, Esa Hämäläinen, Aila Tiitinen, Carl Blomqvist, Johanna Mattson
PURPOSE: To analyze whether monitoring serum estradiol (E2) levels using a highly sensitive and specific liquid chromatography tandem mass spectrometry (LC-MS/MS) method may identify patients with AI failure with E2 levels below the lower limit of quantification (LLOQ) after schwitching from tamoxifen to letrozole. METHODS: In a prospective study of breast cancer patients switching to letrozole treatment after previous tamoxifen, plasma estrogen levels were measured at baseline and after 3- and 12-months using LC-MS/MS...
March 12, 2021: Breast Cancer Research and Treatment
https://read.qxmd.com/read/33538790/efficacy-of-endocrine-therapy-for-the-treatment-of-breast-cancer-in-men-results-from-the-male-phase-2-randomized-clinical-trial
#34
JOURNAL ARTICLE
Mattea Reinisch, Sabine Seiler, Tanja Hauzenberger, Axel Kamischke, Sabine Schmatloch, Hans-Joachim Strittmatter, Dirk-Michael Zahm, Christian Thode, Jenny Furlanetto, Dominika Strik, Volker Möbus, Toralf Reimer, Bruno Valentin Sinn, Elmar Stickeler, Frederik Marmé, Wolfgang Janni, Marcus Schmidt, Christian Rudlowski, Michael Untch, Valentina Nekljudova, Sibylle Loibl
Importance: The extent of changes in estradiol levels in male patients with hormone receptor-positive breast cancer receiving standard endocrine therapies is unknown. The sexual function and quality of life related to those changes have not been adequately evaluated. Objective: To assess the changes in estradiol levels in male patients with breast cancer after 3 months of therapy. Design, Setting, and Participants: This multicenter, phase 2 randomized clinical trial assessed 56 male patients with hormone receptor-positive breast cancer...
February 4, 2021: JAMA Oncology
https://read.qxmd.com/read/33463462/dual-aromatase-sulphatase-inhibitors-dasis-for-the-treatment-of-hormone-dependent-breast-cancer
#35
JOURNAL ARTICLE
Laxmi Banjare, Akhlesh Kumar Jain, Suresh Thareja
Breast cancer is the most frequent diagnosed cancer in women and the second most common form of cancer, causing death after lung cancer, all across the globe at an alarming rate. The level of estrogens, in breast cancer tissues of postmenopausal women is 10-40 folds higher than the non-carcinogenic breast tissues. As a result of this greater level of estrogen, breast tissue becomes more prone to develop breast cancer; mainly estradiol plays a significant role in the initiation and development of hormone dependent breast cancer...
January 19, 2021: Mini Reviews in Medicinal Chemistry
https://read.qxmd.com/read/33392838/predictors-and-outcomes-in-breast-cancer-patients-who-did-or-did-not-pursue-fertility-preservation
#36
JOURNAL ARTICLE
Molly B Moravek, Rafael Confino, Angela K Lawson, Kristin N Smith, Ralph R Kazer, Susan C Klock, William J Gradishar, Jacqueline S Jeruss, Mary Ellen Pavone
PURPOSE: Breast cancer is the most common cancer in reproductive age women, and treatment can affect fertility; however, there is often concern regarding the safety of increased estradiol (E2 ) levels and potential delays in treatment with ovarian stimulation for fertility preservation (FP). The aim of this study was to compare recurrence and survival in breast cancer patients who pursued FP without concurrent letrozole to those who did not (non-FP). METHODS: We reviewed charts of women with breast cancer who contacted the FP patient navigator (PN) at Northwestern University from 01/2005-01/2018...
April 2021: Breast Cancer Research and Treatment
https://read.qxmd.com/read/33323970/hormonal-modulation-of-esr1-mutant-metastasis
#37
JOURNAL ARTICLE
Guowei Gu, Lin Tian, Sarah K Herzog, Yassine Rechoum, Luca Gelsomino, Meng Gao, Lili Du, Jin-Ah Kim, Derek Dustin, Hin Ching Lo, Amanda R Beyer, David G Edwards, Thomas Gonzalez, Anna Tsimelzon, Helen J Huang, Natalie M Fernandez, Sandra L Grimm, Susan G Hilsenbeck, Dan Liu, Jun Xu, Alyssa Alaniz, Shunqiang Li, Gordon B Mills, Filip Janku, Ralf Kittler, Xiang H-F Zhang, Cristian Coarfa, Charles E Foulds, W Fraser Symmans, Sebastiano Andò, Suzanne A W Fuqua
Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases...
February 2021: Oncogene
https://read.qxmd.com/read/33154982/ultrasensitive-serum-estradiol-measurement-by-liquid-chromatography-mass-spectrometry-in-postmenopausal-women-and-mice
#38
JOURNAL ARTICLE
David J Handelsman, Emma Gibson, Susan Davis, Blanka Golebiowski, Kirsty A Walters, Reena Desai
Accurate measurement of very low circulating estradiol (E2 ) (<5 pg/ml) in postmenopausal women and in mice is essential to investigating sex steroid action in target tissues. However, direct immunoassays are too inaccurate and conventional mass spectrometry-based measurement too insensitive at these serum E2 levels. We report application of an ultrasensitive method using a novel estrogen-selective derivatization in liquid chromatography-mass spectrometry to measure serum E2 , with a detection limit of 0...
September 1, 2020: Journal of the Endocrine Society
https://read.qxmd.com/read/33135396/impact-of-sex-hormones-dysregulation-and-adiposity-on-the-outcome-of-postmenopausal-breast-cancer-patients
#39
REVIEW
Danila Coradini, Saro Oriana
Epidemiological studies demonstrated that, in postmenopausal women, high circulating levels of testosterone, especially when associated with weight gain, positively correlated with an increased risk of breast cancer because of the augmented production of oestrogen via testosterone aromatization in the adipose tissue. Besides, growing evidence suggests that sulfatase can increase the tissue concentration of bioactive estradiol through the reconversion of estrone sulfate, thus providing a favourable milieu for epithelial cells expressing the oestrogen receptor...
February 2021: Clinical Obesity
https://read.qxmd.com/read/33131234/controlled-ovarian-hyperstimulation-for-fertility-preservation-in-women-with-breast-cancer-practical-issues
#40
JOURNAL ARTICLE
So Yun Park, Kyungah Jeong, Eun Hye Cho, Hye Won Chung
In Korean women, a westernized lifestyle is associated with an increased risk of breast cancer. Fertility preservation has become an increasingly important issue for women with breast cancer, in accordance with substantial improvements in survival rate after cancer treatment. The methods of controlled ovarian hyperstimulation (COH) for fertility preservation in breast cancer patients have been modified to include aromatase inhibitors to reduce the potential harm associated with increased estradiol levels. Random-start COH and dual ovarian stimulation are feasible options to reduce the total duration of fertility preservation treatment and to efficiently collect oocytes or embryos...
March 2021: Clinical and Experimental Reproductive Medicine
keyword
keyword
158880
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.